BIOREGENX, INC.
BRGXOTCTechnology · Services-Computer Programming, Data Processing, Etc. · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $1.9M | $2.3M | $3.4M | $42,159 | $198,584 |
| Operating income | −$1.2M | −$22.8M | −$3.4M | −$78,308 | −$165,118 |
| Net income | −$1.5M | −$23.1M | −$3.6M | −$78,308 | −$96,873 |
| Total assets | $410,986 | $508,535 | $865,750 | $59,149 | $127,762 |
| Total liabilities | $4.9M | $3.9M | $2.9M | $260,691 | $211,996 |
| Equity | −$4.5M | −$3.4M | −$2.1M | −$2.5M | −$84,234 |
| EPS (diluted) | $0.00 | $-0.03 | $-0.01 | $0.00 | $0.00 |
| Shares out. | 957.0M | 956.6M | 273.8M | 269.7M | 269.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −67.1%
- Net margin
- −83.2%
- Return on equity
- 34.0%
- Return on assets
- −375.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 1204.0%
- Debt / equity
- —
- Book value / share
- $-0.00
- Revenue growth (YoY)
- −20.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -376.61distress
- Accruals / assets
- −385.1%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Strong return on equity (>15%)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 12, 2024
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Dec 31, 2025 | 9,956 | 1.0 | -84.9% |
| Dec 15, 2025 | 65,956 | 1.0 | +100.0% |
| Oct 15, 2025 | 5,579 | 1.0 | -96.5% |
| Sep 30, 2025 | 161,579 | 1.0 | +100.0% |
| Jun 30, 2025 | 10,681 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeApr 14, 2025
- Director / officer changeJan 22, 2025
- Director / officer changeOct 11, 2024
- Director / officer changeJul 23, 2024
- Director / officer changeJul 15, 2024
- Changed auditor · Prior financials not reliable (restatement)Jun 11, 2024
- Changed auditorMay 16, 2024
- Completed an acquisition or disposition · Unregistered equity sale · Change in control · Director / officer change · Amended charter or bylawsApr 1, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-Q FOR MAR 2026May 20, 2026
- NT 10-QEXTENSIONMay 15, 2026
- 10-KFORM 10-K FOR DEC 2025Apr 15, 2026
- NT 10-KEXTENSIONApr 1, 2026
- 10-QFORM 10-Q FOR SEP 2025Nov 14, 2025
- 10-QFORM 10-Q FOR JUNE 2025Aug 14, 2025
- 10-QFORM 10-Q FOR MAR 2025May 15, 2025
- 10-K/AFORM 10-K FOR DEC 2024Apr 16, 2025
- 10-KFORM 10-K FOR DEC 2024Apr 15, 2025
- 8-KFORM 8-KApr 14, 2025
- NT 10-KApr 1, 2025
- 8-KFORM 8-KJan 22, 2025
- 3Jan 2, 2025
- 10-QFROM 10-Q FOR SEPT 2024Nov 14, 2024
- 8-KFORM 8-KOct 11, 2024